ARECOR THERAPEUTICS -,01 Aktie

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, ARECOR THERAPEUTICS -,01 Aktie had revenue of €225.2K and net profit of -€3.46M

(EUR)	June 2026	YoY
Revenue	225.2K	-
Gross profit	42.95K	-
Net profit	-3.46M	-
EBITDA	-3.73M	-

Fundamentals

Metric	Value
Market capitalization	€42.02M
Number of shares	45.3M
52-week high/low	€1.14 - €0.66
Dividends	No
Beta	-0.21
P/E ratio	155.00
PEG ratio	-3.79
P/B ratio	7.94
P/S ratio	-369.56

Company profile

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.